PR Newswire,01.15.2024, reports that according to the DelveInsight Business Research, LLP analysis, “Lyme Disease Treatment Market is Expected to Showcase Significant Growth by 2032.”
Search Results for: treatment
Journal of Infectious Disease (Vydyam, P., et al.) 01.03.2024 published ahead of print “Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.” In this study, researchers demonstrate that treatment with tafenoquine (antimalarial drug) inhibits the growth of multiple Babesia species in vitro, shows great effectiveness against both Babesia microti and Babesia duncani in mice, and protects against lethal infection in animals from atovaquone-sensitive and resistant of B. duncani strains.
JAMA Network Open (Starke, SJ, et al.) 12.12.2023, published online “Time to Diagnosis and Treatment of Lyme Disease by Patient Race.” Investigators found that Black patients were more likely to be diagnosed with disseminated manifestations and experience longer time to appropriate treatment. This is one of the few large studies of racial differences in Lyme disease in an academic setting and is consistent with findings of prior surveillance and insurance claims studies.
eBioMedicine (Vrijmoeth, H.D., et al.) 11.27.2023 published “Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.” In this study, researchers assessed 1135 physician-confirmed Lyme disease patients from the time of initiation of treatment with antibiotics to a one year follow-up. Findings showed that the determinants of persistent symptoms after Lyme disease infections and initial treatment were considered “mainly generic.” Determinants of 295 patients with persistent symptoms included a baseline of physical and social functioning that was poorer, depression and anxiety scores that were higher, illness perceptions that were more negative, as well as having baseline comorbidities, fatigue, cognitive impairment, and pain.
Frontiers (Alruwaili, Y., et al.) 11.21.2023, published “Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease.” This article delves into Lyme disease caused by Borrelia burgdorferi, a prevalent tick-borne infection in North America. While most cases are treatable with antibiotics, a subset of patients experiences chronic symptoms known as […]
GlobalData reported 10.28.2023, “Psilocybin by Ceruvia Lifesciences for Obsessive-Compulsive Disorder: Likelihood of Approval.” Ceruvia Lifesciences focuses on development of neuro-transformational medicines to treat neurological and psychiatric disorders. Psilocybin is a tryptamine alkaloid which is a psychedelic compound that targets 5hydroxytryptamine 1A and 2A. Formulated as a capsule, it is being developed to be administered orally.
Microorganisms (Horowitz, R., et al.) 09.12.2023, published in a special issue Bartonella and Bartonellosis: New Advances and Further Challenges), “Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose […]
The Parasites & Vectors Journal (Arahirwa V., et al.) 08.24.2023, published “Impact of the COVID-19 pandemic on delays in diagnosis and treatment of tick-borne diseases endemic to southeastern USA.” This article talks about how the COVID-19 pandemic affected the diagnosis and treatment of diseases transmitted by ticks, like Lyme disease.
The COVID-19 pandemic caused delays in diagnosing and treating various medical conditions. The impact this has on tick-borne diseases, which can have symptoms similar to COVID-19, hasn’t been well understood. This study looked at patients with suspected tick-borne diseases before and after COVID-19 to see if there were delays in diagnosing and treating these diseases during the pandemic.
JAMA (Raison, C.L., eta al.) 8.31.2023 published “Single-Dose Psilocybin Treatment for Major Depressive Disorder – A Randomized Clinical Trial.” In this study, researchers evaluated single dose psilocybin for its antidepressant […]